NASDAQ
10x Genomics, Inc. (TXG)
♥ 448 Thanks from members
10x Genomics, Inc. (TXG) exhibits strong positive market momentum following a better-than-expected Q2 2026 earnings report, upwardly revised full-year revenue guidance, and multiple analyst price target increases, despite ongoing concerns regarding slowing top-line growth and quarterly net losses.